Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

Core Insights - Acumen Pharmaceuticals announced new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193), a novel therapeutic targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease treatment [1][2][3] Group 1: Study Findings - The Phase 1 study highlighted the strength of the study design and the potential of sabirnetug as a best-in-class treatment for early symptomatic Alzheimer's disease [3] - Sabirnetug demonstrated selective target engagement of AβOs, which are toxic forms of amyloid beta that contribute to neurodegeneration [2][6] - Three administrations of sabirnetug significantly lowered cerebrospinal fluid (CSF) levels of synaptic biomarkers, indicating its mechanism of action [4] Group 2: Patient Experience - Acumen incorporated patient feedback from exit interviews in the INTERCEPT-AD trial to understand their experiences and expectations for treatment [3] - Participants expressed a desire for treatments that would prevent disease progression and maintain cognitive functions, such as recognizing loved ones [3] Group 3: Ongoing Trials - The ongoing Phase 2 clinical trial, ALTITUDE-AD, aims to evaluate the efficacy and safety of sabirnetug in approximately 540 individuals with early Alzheimer's disease [5][8] - The trial is currently enrolling participants at multiple sites in the U.S., Canada, and plans to expand to Europe and the UK [5][8] Group 4: Assay Development - Acumen developed an ultra-sensitive assay to detect total levels of sabirnetug in CSF, which will aid in quantifying drug exposure in clinical trials [4]